Neural Stimulation Technology Offers Improved Treatment of Chronic Pain
the Neurology Advisor take:
Drug Free Therapeutix LLC, a life sciences startup based out of Purdue University, has developed technology that can improve the quality of life in patients whose chronic pain isn’t well managed through conventional drug therapy.
Patients that elect to undergo neural stimulation treatments must often face a lengthy period of customization in order to achieve the best results.
"These neural stimulation treatments also are used to treat certain autoimmune inflammatory disorders, anxiety disorders, depression, epilepsy, urinary incontinence and other ailments," Matthew P. Ward, PhD, founder and chief science officer at Drug Free Therapeutix, said. "However, most available treatments must be manually customized over a long period of time to offer optimal, patient-centric relief."
The startup’s technology, EXACT, which stands for Extraneural Activation Control Technology, can reduce customization times from over two years to less than five minutes, transforming the existing inputs into a set of dials that can directly control and maintain the level of pain relief.
"Using devices under EXACT control, patients will for the first time have a way to directly convey their unique and deeply personal experience of pain to the stimulator, teaching it how to best meet their therapeutic needs over time,” Ward said.
The company hopes to obtain regulatory approval for EXACT and then partner with medical device companies to create new products and services around the technology within three to five years.
Improving Stimulation Treatments for Patients with Chronic Pain
Drug Free Therapeutix LLC, a life sciences startup based out of Purdue University, says its technology may increase the quality of life for patients who suffer from chronic pain that cannot effectively be managed through conventional drug therapy.The technology, Medical Design Technology magazine reports, offers a highly-personalized pain management experience in a reduced amount of time.
Next Article in Pain
Neurology Advisor Articles
- Guidance for Antibiotic Use in Myasthenia Gravis
- Lorcaserin May Reduce Motor Seizures in Pediatric Treatment-Resistant Epilepsy
- FDA Warns of Rare Stroke Risk With Multiple Sclerosis Drug
- Rituximab Effects in Neuromyelitis Optica Spectrum Disorders
- Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis
- Migraine With Aura Linked to Increase in Incident A-Fib
- TBI Increases Dementia Risk in Middle-Age and Elderly Patients With T1D
- NIHSS May Misjudge Infratentorial Lesions in Thrombolysis-Eligible Stroke
- Study Identifies Area Postrema Syndrome Identification Criteria in NMOSD
- Neurofilament Light Biomarkers Identify Alzheimer Disease Risk in Down Syndrome